Belatacept Conversion in an HIV-Positive Kidney Transplant Recipient With Prolonged Delayed Graft Function

2016 ◽  
Vol 16 (11) ◽  
pp. 3278-3281 ◽  
Author(s):  
Z. Ebcioglu ◽  
C. Liu ◽  
R. Shapiro ◽  
M. Rana ◽  
F. Salem ◽  
...  
2008 ◽  
Vol 40 (7) ◽  
pp. 2435-2436
Author(s):  
Y.L. Thye ◽  
S.K. Lim ◽  
C.M. Wong ◽  
T.C. Keng ◽  
Y.B. Chong ◽  
...  

2009 ◽  
Vol 87 (4) ◽  
pp. 618-619 ◽  
Author(s):  
Roberto C. Manfro ◽  
Jose A. Pedroso ◽  
Karla L. Pegas ◽  
Luiz Felipe S. Gonçalves

2019 ◽  
Vol 30 (9) ◽  
pp. 919-922 ◽  
Author(s):  
Gaetano Alfano ◽  
Francesco Fontana ◽  
Giacomo Mori ◽  
Emanuela Vicari ◽  
Giovanni Dolci ◽  
...  

Sirolimus (SIR) is a potent immunosuppressive agent with multiple proprieties. We report beneficial antiviral effects of SIR in an HIV-positive kidney transplant recipient who experienced low-level HIV-1 replication. The immunosuppressive agent was well tolerated by the patient, and no side effects were reported during follow-up. Despite immunosuppressive monotherapy, SIR ensured stable graft function.


AIDS ◽  
2017 ◽  
Vol 31 (6) ◽  
pp. 872-873
Author(s):  
Viyaasan Mahalingasivam ◽  
Esther Gathogo ◽  
Kate Bramham ◽  
Frank A. Post

2020 ◽  
Vol 22 (5) ◽  
Author(s):  
Rebecca N. Kumar ◽  
Sajal D. Tanna ◽  
Aneesha A. Shetty ◽  
Valentina Stosor

1996 ◽  
Vol 62 (10) ◽  
pp. 1509-1511 ◽  
Author(s):  
Motonobu Nishimura ◽  
Kenichi Yamada ◽  
Kazuyuki Matsushita ◽  
Kaoru Sakamoto ◽  
Takashi Saisu ◽  
...  

2020 ◽  
Vol 39 (2) ◽  
pp. 89-94
Author(s):  
Riza Madazlı ◽  
Didem Kaymak ◽  
Verda Alpay ◽  
Hakan Erenel ◽  
M. Tamer Dincer ◽  
...  

2020 ◽  
Vol 382 (2) ◽  
pp. 195-197 ◽  
Author(s):  
Maria Blasi ◽  
Hannah Stadtler ◽  
Jerry Chang ◽  
Marion Hemmersbach-Miller ◽  
Christina Wyatt ◽  
...  

2018 ◽  
Vol 3 (1) ◽  
pp. 238146831878181 ◽  
Author(s):  
Devin Incerti ◽  
Nicholas Summers ◽  
Thanh G. N. Ton ◽  
Audra Boscoe ◽  
Anil Chandraker ◽  
...  

Background. Although delayed graft function (DGF) is associated with an increased risk of acute rejection and decreased graft survival, there are no estimates of the long-term or lifetime health burden of DGF. Objectives. To estimate the long-term and lifetime health burden of DGF, defined as the need for at least one dialysis session within the first week after transplantation, for a cohort representative of patients who had their first kidney transplant in 2014. Methods. Data from the United States Renal Data System (USRDS; 2001–2014) were used to estimate a semi-Markov parametric multi-state model with three disease states. Maximum length of follow-up was 13.7 years, and a microsimulation model was used to extrapolate results over a lifetime. The impact of DGF was assessed by simulating the model for each patient in the cohort with and without DGF. Results. At the end of 13.7 years of follow-up, DGF reduces the probability of having a functioning graft from 52% to 32%, increases the probability of being on dialysis from 10% to 19%, and increases the probability of death from 38% to 50% relative to transplant recipients who do not experience DGF. A typical transplant recipient with DGF (median age = 53) is observed to lose 0.87 quality-adjusted life-years (QALYs). Extrapolated over a lifetime, the same 53-year-old DGF patient is projected to lose 3.01 (95% confidence interval: 2.33, 3.70) QALYs relative to a transplant recipient with the same characteristics who does not experience DGF. Conclusions. The lifetime health burden of DGF is substantial. Understanding these consequences will help health care providers weigh kidney transplant decisions and inform policies for patients in the context of varying risks of DGF.


Sign in / Sign up

Export Citation Format

Share Document